Last updated: July 5, 2023
Sponsor: Peter Humaidan
Overall Status: Active - Recruiting
Phase
2
Condition
Infertility
Treatment
Placebo
Clindamycin
Clinical Study ID
NCT05166746
AVM_Lacto_2015/582
Ages 18-42 Female
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Abnormal vaginal microbiota.
- The screening swab should be repeated if more than 3 months old.
- HIV, Hepatitis B or C positivity.
- First, second or third IVF stimulation cycle or embryo transfer therefrom.
- BMI<35
- Written informed consent.
Exclusion
Exclusion Criteria:
- Known or suspected hypersensitivity to clindamycin.
- HPV CIN 2 or higher.
- Former or current inflammatory bowel disease
- Severe concomitant disease, including diabetes.
- MAX 2 embryos may be transferred
- Artificial heart valve
- Intrauterine malformations with operation indication as determined by treatingphysician (Polyps, Septum, fibroma)
Study Design
Total Participants: 333
Treatment Group(s): 2
Primary Treatment: Placebo
Phase: 2
Study Start date:
December 07, 2017
Estimated Completion Date:
October 01, 2023
Connect with a study center
Copenhagen University Hospital, Rigshospitalet
Copenhagen, 2100
DenmarkActive - Recruiting
Stork Fertility Clinic VivaNeo
Copenhagen, 2100
DenmarkActive - Recruiting
Hvidovre Hospital, The Fertility Clinic
Hvidovre, 2650
DenmarkActive - Recruiting
Fertility Clinic Skive, Skive Regional Hospital
Skive, 7800
DenmarkActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.